Cryolipolysis complication statistics: the real PAH rates, the FDA reports, and why men keep showing up
Published PAH rates after fat freezing span 0.0051% to 0.67%. Here is every real number with its source, plus our own count of the FDA's reports.
You are holding a quote for fat freezing on your double chin or love handles, and you have just been told the serious complication happens “less than one in a thousand” times. That sounds close to zero.
Then you find a different figure. One paper reports 0.67%; another reports 0.0051%. Both get presented as the risk. That is a 131-fold spread.
Absolute risk is low. The low number is still not the whole story, and the sections below keep published rates, FDA reports, recalls and the male signal apart instead of blending them.
Key numbers
- 131-fold — spread across published PAH estimates Jalian 2014
- 0.22% — pooled PAH incidence, 28 studies Mah 2025
- 0.67% — highest published estimate Cox 2022
- 11,222 — CoolSculpting reports in our FDA count openFDA
- 99.6% — of them dated 2021 or later FDA MAUDE
- 55% — of PAH patients in Nikolis were male Nikolis 2021
- 12,072 — applicator units pulled in 2022 FDA recalls
Table of contents
- How often does paradoxical adipose hyperplasia actually happen?
- Why does the same complication have five different rates?
- Are men more likely to get it?
- What is in the FDA's database, and what it cannot tell you
- What happened with the recalls?
- What we could not verify
- What this means if you are booked in next week
- How to cite this page
- The bottom line
- Sources
How often does paradoxical adipose hyperplasia actually happen?
Published PAH rates are not one number. Risk is low at every estimate. Clinics quote the low figure: the manufacturer’s 0.025%; other estimates use longer follow-up and older applicators. Thin evidence is the norm here; our cosmetic-procedure evidence index shows how little sits behind most appearance procedures.
| Source | Reported PAH rate | What it counted |
|---|---|---|
| Jalian 2014 | 0.0051% | Case report incidence estimate |
| Singh 2015 | 0.47% | 2 in 422 cryolipolysis treatments |
| Nikolis 2021 | 0.05%–0.39% per treatment cycle | 8,658 cycles in 2,114 patients |
| Cox 2022 | 0.67% | 4 diagnosed patients at one academic centre |
| Mah 2025 meta-analysis | 0.22% | 28 studies, 13,078 patients, 29 PAH cases |
Mah’s pooled figure is about 1 in 455 patients. Jalian’s is where the 1 in 20,000 line comes from.
None of these are head-to-head tests, so read the range as uncertainty about detection and context, not as a promise about your own odds.
Why does the same complication have five different rates?
Denominator first: a rate per cycle is not a rate per patient, and one patient buys several cycles.
Follow-up second. Mah found only 4 studies reported follow-up of at least 16 weeks, while FDA says reported cases developed two to five months afterwards — a study that stops at eight weeks cannot count what has not appeared yet.
Device generation third. Nikolis reported rates fell by over 75% at every site once newer units were used, and 76.9% of cases involved older ones. A rate is incomplete unless the clinic says which applicator generation produced it.
Are men more likely to get it?
The male signal is repeated but unsettled: the case literature keeps containing a disproportionate share of men, and the best pooled analysis found no statistically significant sex difference.
Keaney and Naga put it in their 2016 title, “Men at risk for paradoxical adipose hyperplasia after cryolipolysis.” Nikolis found 55% of PAH patients were male. Kelly’s series was 8 men and 3 women, 7 of the 11 needing surgery. Jalian wrote that it seemed more common in male patients; Singh’s two cases were both men, aged 44 and 52.
The counterweight is real: Mah’s 2025 meta-analysis found sex-based differences were not statistically significant, and Keaney’s mechanism — sexual dimorphism in adipose anatomy — is a hypothesis, not a calculator.
Hold both. Men are a minority of cosmetic-procedure patients, as our male plastic surgery statistics page shows, yet men keep turning up in the cases. A pooled test missing significance across 29 cases is not evidence of no difference; it is evidence nobody has enough cases. Ask the clinic for its own count.
What is in the FDA's database, and what it cannot tell you
MAUDE is a report archive, not an incidence registry. Our own count, run on 25 September 2026, found 11,222 reports on a brand-name search for CoolSculpting.
Of those, 10,477 — 93.4% — have a narrative naming PAH. Only 41 predate 2021; 11,181, or 99.6%, are 2021 or later:
- 2020: 6 reports
- 2021: 1,097 reports
- 2022: 1,966 reports
- 2023: 5,490 reports
- 2024: 1,269 reports
- 2025: 916 reports
2023 alone is nearly half of every report ever filed naming the device. The manufacturer filed 99.1% of them; only 104 came voluntarily from anyone else. The database codes 98.2% as Injury rather than Malfunction, exactly 1 as a Death, and 96.8% with the outcome “Required Intervention.” FDA’s own cryolipolysis product code, OOK, returns 11,460 reports across all brands.
The sex field is thinner than it looks: missing from 1,847 reports, 16.5%, and among those that record one, 24.3% are men — 2,281 of 9,375. Juvederm's field is blank in 6,027 of 9,894. As a witness to what happens to men, the database is poor. For chest tissue see our gynecomastia statistics; for a submental pad that survived getting lean, double chin when skinny.
We will say the uncomfortable part ourselves: FDA states this data must not be used to evaluate event rates, changes in rates over time, or comparisons between devices — and a year curve is a change over time. We publish it because the curve reflects reporting, not biology; nobody should divide 11,222 by an imagined denominator and call it risk.
The device did not change in 2021. The litigation did.
What happened with the recalls?
Two failure stories. The 2021 recall covered 911 systems, revised upward to 1,105, over software that could fail to report a thermal event and let an operator keep treating. In June 2022 Zeltiq Aesthetics removed 5 CoolSculpting applicator models totalling 12,072 units, citing an increased complaint rate for paradoxical hyperplasia between 2019 and 2021.
FDA listed the 2022 root cause as “Unknown/Undetermined by firm.” It was Class II and still Ongoing when we checked on 25 September 2026, over four years after it began on 9 June 2022. The applicators — CoolMax, CoolCore, CoolCurve, CoolCurve+ and CoolFit, recall numbers Z-1346-2022 through Z-1350-2022 — are worth knowing by name, because Mah found 10 of 29 PAH cases, 34.5%, involved the CoolCore. The recall and enforcement records are the primary documents.
What we could not verify
Five popular claims did not survive a source check.
- We searched for the marketed 95% satisfaction figure and found no primary source. The 2025 meta-analysis of 30 studies and 3,158 participants reports 80.4%.
- We searched PubMed for the claim that cryolipolysis destroys 20% to 25% of fat cells in the treated area: 0 records for that phrasing.
- We searched for a worldwide treatment denominator and found nothing beyond the “over 650,000 cycles” stated in 2014.
- We searched MAUDE for a way to count the distinct people behind those 10,477 narratives: none exists, because reports are not deduplicated per patient.
- We searched the recall records and found the 12,072 units distributed but no recovery figure.
What this means if you are booked in next week
Three questions have factual answers: which applicator generation will be used, how long follow-up runs, and how many PAH cases that clinic has seen. A vague answer to any of them is itself the finding.
FDA states that PAH does not go away on its own, that these devices do not treat obesity and will not produce weight loss, and that under the jawline they can cause nerve damage that temporarily moves the lip or tongue. In Cox’s series all 4 diagnosed patients needed liposuction, abdominoplasty or both; in Kelly’s, 7 of 11 needed surgery. None of that predicts your outcome. It does explain why “rare” should not become “irrelevant.”
If the reason for the treatment is how you read to other people, our free perception test gives you that read before you pay—no paywall on your score, a description of the impression rather than a beauty score, and not a clinical instrument. If the worry is sliding into a body-image spiral, our body dysmorphia statistics page is the better path.
How to cite this page
Real World Appeal, “Cryolipolysis complication statistics,” https://realworldappeal.com/blog/cryolipolysis-complication-statistics, accessed 25 September 2026.
The bottom line
Absolute risk is low, published PAH estimates span 0.0051% to 0.67%, the pooled figure is 0.22%, and the 11,222 FDA reports are a reporting curve rather than an incidence rate. The male signal repeats across case series without being settled.
A rate is only honest when you can see its denominator, its device generation, its follow-up window and who filed it. For a man booking fat freezing, “rare” is where the questions start.
Sources
- U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience Database (MAUDE). fda.gov
- U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. fda.gov
- openFDA device adverse event, recall and enforcement APIs, queried 25 September 2026. open.fda.gov
- Jalian HR, Avram MM, Garibyan L, et al. (2014). Paradoxical adipose hyperplasia after cryolipolysis. JAMA dermatology, 150(3), 317-9. PubMed 24382640
- Singh SM, Geddes ER, Boutrous SG, et al. (2015). Paradoxical adipose hyperplasia secondary to cryolipolysis: An underreported entity?. Lasers in surgery and medicine, 47(6), 476-8. PubMed 26096832
- Keaney TC & Naga LI (2016). Men at risk for paradoxical adipose hyperplasia after cryolipolysis. Journal of cosmetic dermatology, 15(4), 575-577. PubMed 27432593
- Ho D & Jagdeo J (2017). A Systematic Review of Paradoxical Adipose Hyperplasia (PAH) Post-Cryolipolysis. Journal of drugs in dermatology : JDD, 16(1), 62-67. PubMed 28095535
- Kelly ME, Rodríguez-Feliz J, Torres C, et al. (2018). Treatment of Paradoxical Adipose Hyperplasia following Cryolipolysis: A Single-Center Experience. Plastic and reconstructive surgery, 142(1), 17e-22e. PubMed 29952891
- Nikolis A & Enright KM (2021). A Multicenter Evaluation of Paradoxical Adipose Hyperplasia Following Cryolipolysis for Fat Reduction and Body Contouring: A Review of 8658 Cycles in 2114 Patients. Aesthetic surgery journal, 41(8), 932-941. PubMed 33216910
- Cox EA, Nichols DS, Riklan JE, et al. (2022). Characteristics and Treatment of Patients Diagnosed With Paradoxical Adipose Hyperplasia After Cryolipolysis: A Case Series and Scoping Review. Aesthetic surgery journal, 42(12), NP763-NP774. PubMed 35961054
- Ravindran R, Pizzol D, Rahmati M, et al. (2025). Cryolipolysis and associated health outcomes, adverse events, and satisfaction: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 26(8), e13925. PubMed 40211915
- Mah AE, Razeghi P, Li C, et al. (2025). Incidence of Paradoxical Adipose Hyperplasia After Cryolipolysis: A Systematic Review and Meta-Analysis. Aesthetic surgery journal. Open forum, 7, ojaf142. PubMed 41322038
Frequently asked questions
How common is paradoxical adipose hyperplasia after fat freezing?
The pooled estimate is 0.22%, but published estimates range from 0.0051% to 0.67% because studies use different denominators, devices, and follow-up windows. The lower figure is the one most often quoted, while later reviews suggest the true rate may be higher. See the cosmetic-procedure evidence index for the wider evidence map.
Is paradoxical adipose hyperplasia more common in men?
Several case series point in that direction: Keaney and Naga titled their paper “Men at risk,” Nikolis found 55% of PAH patients were male, and Kelly reported 8 men among 11 cases. The 2025 meta-analysis found the sex difference was not statistically significant, so the honest answer is a repeated male signal without a settled relative-risk estimate. Our male plastic surgery statistics page gives the broader context.
Does paradoxical adipose hyperplasia go away on its own?
No. The FDA says reported cases developed two to five months after fat freezing and that PAH does not go away on its own. The usual correction is procedural, which is why a clinic’s follow-up plan matters.
Do the FDA's 11,222 CoolSculpting reports mean it is dangerous?
No. The count is a report total, not an incidence rate: reporting surged in later years, the manufacturer filed 99.1% of reports, and FDA warns that MAUDE cannot establish incidence, prevalence, cause, or changes in event rates. A large report count deserves scrutiny, but it cannot be divided by an unknown treatment denominator to produce risk.
Does fat freezing under the chin change how your face reads?
It can change the jawline, which is the part of body contouring most directly connected to first impressions. The FDA lists nerve damage that can temporarily change the position of the lip or tongue when a device is used under the jawline. The useful question is not only whether the contour changes, but whether the change improves the read you care about.